EXSERVAN Drug Insight and Market Forecast – 2032

EXSERVAN Drug Insight and Market Forecast – 2032

“EXSERVAN Drug Insight and Market Forecast – 2032” report provides comprehensive insights about EXSERVAN for Amyotrophic Lateral Sclerosis in seven major markets. A detailed picture of the EXSERVAN for Amyotrophic Lateral Sclerosis in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the EXSERVAN for Amyotrophic Lateral Sclerosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EXSERVAN market forecast analysis for Amyotrophic Lateral Sclerosis in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

EXSERVAN, formerly known as AQST-117 is an oral Riluzole film used to treat Amyotrophic Lateral Sclerosis. EXSERVAN consists of a thin film that is placed on the tongue, utilizes the company’s “PharmFilm” technology. The dissolving oral film can be taken twice daily without water, making it easier for patients who have difficulty swallowing pills or liquids. EXSERVAN offers an easy alternative to tablets, liquids, or other traditional forms of medication as it can be taken without water or the need to use swallowing muscles. After receiving a regulatory nod from the US FDA, Aquestive Therapeutics is in the EMA approval process for EXSERVAN (Muscular Dystrophy Association, 2019).

The recommended dosage for EXSERVAN is 50 mg taken orally twice daily. EXSERVAN should be taken at least 1 hour before or 2 hours after a meal. (US FDA, 2020)

Scope of the Report

The report provides insights into:

A comprehensive product overview including the EXSERVAN description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.

Elaborated details on EXSERVAN regulatory milestones and other development activities have been provided in this report.

The report also highlights the EXSERVAN research and development activities in Amyotrophic Lateral Sclerosis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around EXSERVAN.

The report contains forecasted sales of EXSERVAN for Amyotrophic lateral sclerosis till 2032.

Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.

The report also features the SWOT analysis with analyst views for EXSERVAN in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EXSERVAN Analytical Perspective by DelveInsight

In-depth EXSERVAN Market Assessment

This report provides a detailed market assessment of EXSERVAN for Amyotrophic lateral sclerosis in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

EXSERVAN Clinical Assessment

The report provides the clinical trials information of EXSERVAN for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EXSERVAN dominance.

Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to EXSERVAN and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EXSERVAN in Amyotrophic Lateral Sclerosis.

Our in-depth analysis of the forecasted sales data of EXSERVAN from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EXSERVAN in Amyotrophic Lateral Sclerosis.

Key Questions

What is the product type, route of administration and mechanism of action of EXSERVAN?

What is the clinical trial status of the study related to EXSERVAN in Amyotrophic lateral sclerosis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EXSERVAN development?

What are the key designations that have been granted to EXSERVAN for Amyotrophic Lateral Sclerosis?

What is the forecasted market scenario of EXSERVAN for Amyotrophic Lateral Sclerosis?

What are the forecasted sales of EXSERVAN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to EXSERVAN for Amyotrophic Lateral Sclerosis?

Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?